Sertraline for social phobia: A double-blind, placebo-controlled crossover study

David J. Katzelnick, Kenneth A. Kobak, John H. Greist, James W. Jefferson, Julia M. Mantle, Ronald C. Serlin

Research output: Contribution to journalArticlepeer-review

242 Scopus citations


Objective: The authors examined the efficacy of sertraline in the treatment of social phobia. Method: In a double-blind crossover study, 12 outpatients were randomly assigned to 10 weeks of sertraline (50-200 mg/day, flexible dosing) and 10 weeks of placebo. Results: A statistically significant improvement in scores on the Liebowitz Social Anxiety Scale was found with sertraline but not with placebo. There was no significant difference between scores obtained with computer- and clinician-administered versions of the Liebowitz Social Anxiety Scale, and the majority of patients preferred to be interviewed by the computer. Conclusions: Sertraline seems a safe and effective treatment for social phobia, and computer administration may be a preferable mode of assessment with socially phobic patients.

Original languageEnglish (US)
Pages (from-to)1368-1371
Number of pages4
JournalAmerican Journal of Psychiatry
Issue number9
StatePublished - Sep 1995

ASJC Scopus subject areas

  • Psychiatry and Mental health


Dive into the research topics of 'Sertraline for social phobia: A double-blind, placebo-controlled crossover study'. Together they form a unique fingerprint.

Cite this